Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

991
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
991
Seizures: Classification01:13

Seizures: Classification

1.1K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

670
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
670

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of nationwide folic acid fortification on genetic variants associated with conotruncal heart defects.

Research square·2026
Same author

A population-based study of the co-occurrence of hypospadias and congenital heart defects among boys conceived with in vitro fertilization†.

Human reproduction (Oxford, England)·2026
Same author

Refining Domain-Based Prognostication in DNM1 Encephalopathy: A Mild Phenotype Associated With a GTPase Domain Variant.

American journal of medical genetics. Part A·2026
Same author

Sleep Disturbances in Adults With Tuberous Sclerosis Complex: Influences of Treatment and Clinical Features.

American journal of medical genetics. Part A·2026
Same author

Development of a face-validated conceptual model structure for economic evaluation in phenylketonuria, through expert elicitation.

Orphanet journal of rare diseases·2026
Same author

Early neurodevelopmental outcomes in a child with tuberous sclerosis complex treated with everolimus and vigabatrin.

BMC neurology·2026

Related Experiment Video

Updated: Dec 6, 2025

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury
07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

11.0K

Epilepsy Risk Prediction Model for Patients With Tuberous Sclerosis Complex.

Laura S Farach1, Melissa A Richard2, Philip J Lupo2

  • 1Division of Medical Genetics, Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas.

Pediatric Neurology
|October 4, 2020
PubMed
Summary

Identifying epilepsy risk in tuberous sclerosis complex (TSC) is crucial for early intervention. A predictive model combining genetic factors and tuber presence accurately identifies 73% of at-risk individuals, improving patient outcomes.

Keywords:
EpilepsyGenotypeRisk factorsRisk prediction modelSeizuresTuberous sclerosis complex (TSC)

More Related Videos

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

26.2K
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.2K

Related Experiment Videos

Last Updated: Dec 6, 2025

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury
07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

11.0K
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

26.2K
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.2K

Area of Science:

  • Neurology
  • Genetics
  • Developmental Pediatrics

Background:

  • Individuals with tuberous sclerosis complex (TSC) have a significantly higher risk of developing epilepsy.
  • Early seizure management in TSC is vital for optimizing developmental trajectories.
  • Predicting epilepsy onset in TSC patients remains challenging despite known risk factors.

Purpose of the Study:

  • To evaluate the combined predictive power of established risk factors for epilepsy in individuals with TSC.
  • To develop and validate a clinical risk prediction model for epilepsy in the TSC population.

Main Methods:

  • A cohort of 333 individuals with TSC was analyzed, with epilepsy diagnosis as the primary outcome.
  • Logistic regression was employed to assess the association of sex, TSC genotype, and tuber presence with epilepsy.
  • A comprehensive risk prediction model was constructed, and its discriminative ability was quantified using the area under the curve (AUC).

Main Results:

  • The presence of tubers was identified as the most significant risk factor for epilepsy in TSC patients.
  • Individuals with pathogenic TSC2 variants demonstrated a threefold increased likelihood of seizure development.
  • The integrated risk prediction model achieved an AUC of 0.73, indicating moderate predictive accuracy.

Conclusions:

  • A predictive model integrating simple patient characteristics, including sex, TSC genotype, and tuber presence, can effectively forecast epilepsy risk in TSC.
  • This risk assessment tool correctly identifies epilepsy in 73% of individuals with TSC, facilitating timely clinical intervention.